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Fast oscillation (FO) of an electrooculogram (EOG) was recorded in both eyes of 10 
healthy volunteers before and after administration of metoclopramide hydrochloride 
(MTCL), a D2-selective dopamine receptor antagonist, paying particular attention to sex 
concerning sensitivity to dopamine in young subjects. Healthy volunteers were divided 
into male and female groups; 5 males (10 eyes) aged 21 to 23 years (average, 21.8 years) 
and 5 females (10 eyes) aged 19 to 25 years (average, 21.8 years).  As an FO parameter, 
the dfFO (the averaged difference in µV between maximum amplitude in the dark period 
and minimum amplitude in the light period during FO measurement) was evaluated. 
The mean level of dfFO signiﬁcantly increased between phase A (the initial 10 min before 
intravenous injection of 10 mg of MTCL) and phase B (10 min after the injection) in the 
male and female groups (P < 0.01 and P < 0.025) and between phase A and phase C (the 
additional 10 min after the injection) in both groups (P < 0.01 and P < 0.05).  The mean 
level of dfFO in the female group was signiﬁcantly higher than that of the male group in 
phase B (P < 0.05).  As a control, the experimental procedure was performed with physi-
ological saline administration, and no changes were observed.  The data suggest that 
there exists some difference between young males and females generation concerning 
sensitivity to dopamine and that young females may show a higher-than-male sensitivity 
to dopamine in the occurrence of FO potential.
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Fast oscillation (FO) of the electrooculogram 
(EOG) is the rapid initial deflection of opposite 
polarities occurring at the initial stage of the light 
and dark periods in the EOG procedure (Kolder 
and Brecher, 1966; Kolder, 1974).  That is, FO 
shows a peak in the dark adaptation (dark peak) 
and a trough in the light adaptation (light trough) 
in response to dark and light periods of approxi-
mately 1.1 min each.  FO is distinct from ordinary 
slow oscillation (SO) of the EOG which shows a 
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trough in the dark adaptation (dark trough) and 
a peak in the light adaptation (light peak) in re-
sponse to dark and light periods of approximately 
12.5 min each (Kolder and Brecher, 1966; Kolder, 
1974; Welber, 1989).
 Concerning the origin and occurrence of FO 
and SO, Steinberg and others (1983) reported the 
involvement of the retinal pigment epithelium, 
mainly its basal membrane in the FO potential, 
while Arden and others (1962) reported the in-
volvement of the retinal pigment epithelium and 
photoreceptor complex in the SO potential.
 Joseph and Miller (1991) suggested that the 
downward oscillation of FO might result from 
a delayed hyperpolarization associated with in-
creased electric resistance of the basal membrane 
of the retinal pigment epithelium.  The delayed 
hyperpolarization is thought to be caused by a 
decrease in intracellular chloride, which is linked 
to the light-induced drop in subretinal potassium 
concentration (Joseph and Miller, 1991).  The up-
ward oscillation of FO is thought to result from 
a depolarized change associated with decreased 
electric resistance of the basal membrane of the 
retinal pigment epithelium.  This depolarized con-
dition of the basal membrane may be caused by 
an increase in intracellular chloride of the retinal 
pigment epithelium, which is linked to the dark-
induced recovery in subretinal potassium concen-
tration (Nikara et al., 1974).
 On the other hand, dopamine, a retinal neu-
rotransmitter, has been known to be indispensable 
for the process of generation and delivery of elec-
tric excitement in the ordinary SO potential (Dawis 
and Niemyer, 1986; Jaffe et al., 1987; Gallemore 
et al., 1988; Maruiwa et al., 1992).  According 
to the results of an experiment in a report by 
Maruiwa and others (1992), metoclopramide hy-
drochloride (MTCL), a D2-selective dopamine re-
ceptor antagonist (Schulze-Delrieu, 1979), which 
was given intravenously in 5 healthy volunteers 
aged 23 to 33 years, increased the dark-adapted 
SO amplitudes transiently and suppressed the 
light-adapted SO amplitudes.
 However, little has been known of the reac-
tion and influence of dopamine on the FO po-
tential. In this report, we have tested the effects 
of MTCL on FO in 10 healthy volunteers aged 
19 to 25 years, paying particular attention to the 
existence of difference in sex concerning sensitiv-
ity to dopamine in young subjects, since Nakao 
and others (1994) postulated the possibility in 
their experiment, in which ﬂuctuations in the FO 
potential obtained from female normal subjects 
averaging 22.7 years of age were relatively larger 
than those from normal male subjects averaging 





In this study, 10 healthy volunteers aged 19 to 25 
years with normal, functional eyes (20 eyes), in 
whom error of refraction did not exceed ± 3 di-
opters, were tested at the Department of Ophthal-
mology, Tottori University Hospital.  The healthy 
volunteers were divided into male and female 
groups; 5 males (10 eyes) aged 21 to 23 years (av-
erage, 21.8 years) and 5 females (10 eyes) aged 19 
to 25 years (average, 21.8 years).
 Before the trial, the purpose of the experi-
ment and the tasks to be performed were fully ex-
plained to each volunteer, and written consent was 
obtained. All procedures conformed to the tenets 
of the Helsinki Declaration.
 
Apparatus and methods for FO recording
Using a newly devised automated electrooculo-
graph, a Nidek EOG-2 (Nidek, Gamagori, Japan) 
(Nakao et al., 1994; Inoue et al., 2003; Tamai 
et al., 2004), FO was recorded in each subject. 
The EOG-2 consists of a dome, a personal com-
puter, an index controller, an ampliﬁer, a printer 
and an EOG pen recorder.  Inside the dome is 
a hemispheric screen with a radius of 300 mm. 
Four tungsten lamps (115 V, 50 W each) pro-
duce a background luminance of 1,270 lux when 
measured at the location of the subject’s eyes. In 
this study, the background light was periodically 
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turned on and off at intervals of 1 min with the 
aid of the computer.
 For every subject, cup-shaped silver-silver 
chloride conductive electrodes, 8 mm in diameter, 
were placed beside both canthi of each eye on the 
orbital margin, and a grounding electrode with 
the same cup shape was placed on the left earlobe, 
as routinely used.  Before setting these electrodes, 
the skin was cleaned with 90% alcohol, and then 
the electrodes were applied with a conductive 
paste. Electrode resistance was below 10 kΩ.  Un-
der these conditions, simultaneous recording of 
the FO potentials from each eye of every subject 
was possible.
 Mydriasis can provide better control of reti-
nal illumination.  However, FO recording was 
performed without mydriasis, because mydriasis 
may increase discomfort in subjects.  Before the 
FO recording, a 10-min pre-light adaptation pe-
riod at a background luminance level of 1,270 lux 
was given.  Then the subjects were introduced to 
ﬁxate alternately on a pair of targets on the screen 
inside the dome. The two targets subtended 40˚ to 
the visual angle were presented alternately with a 
frequency of 0.5 Hz.
 After this adaptation period, the dome was 
periodically illuminated for 1 min followed by 1 
min of darkness for 30 min.  The FO potentials 
showed peaks in darkness and troughs in light 
near the end of the dark and light periods respec-
tively; that is, between 45 s and 55 s after the start 
of each period (De Rouck and Kayembe, 1981). 
Therefore, the FO measurements were performed 
at 40 to 60 s in each dark and light period; there 
were 10 measurements in each period.  Six out of 
10 EOG amplitudes were automatically averaged 
and recorded at the end of each period through 
the EOG artifact rejection system on the Nidek 
EOG-2 (Inoue et al., 2003; Tamai et al., 2004). 
In this study, the calibration sensitivity for the pen 
recorder was 200 µV/division on the printer.  The 
time constant of the ampliﬁer was set at 3 s, and a 
high frequency cutoff of –3 dB was set at 20 Hz.
 
Administered agent and control solution
After the initial 10 min of alternating dark and 
light periods (phase A), 10 mg of MTCL in 2 mL 
of Primperan injection (Fujisawa Pharmaceutical 
Co. Ltd., Osaka, Japan) was given intravenously 
from the median cubital vein of each subject in 
less than 10 s.  FO was further recorded for anoth-
er 20 min (phases B and C, 10 min each, respec-
tively).  For the nonchemical control, each subject 
was asked to receive another set of examinations 
with an intravenous injection of 2 mL of physi-
ological saline.  The control examination was 
scheduled after an interval of at least 2 weeks.
 
FO parameter
As an FO parameter, dfFO, which is the averaged 
difference in µV between maximum amplitude in 
the dark period and minimum amplitude in the 
light period during FO measurement (De Rouck 
and Kayembe, 1981; Nakao et al., 2003; Tamai et 
al., 2004) (Fig. 1), was evaluated.  In the present 
study, each phase showed 5 dark-rise and light-fall 
Fig. 1.  Calculation method for dfFO as an 
FO parameter in this survey.  AD, maximum 
amplitude in the dark period; AL, minimum 
amplitude in the light period during FO mea-
surement. n, number of pairs (alternating 
dark-light period of 1 min each), 5 pairs in 
total.  dfFO was calculated only if at least 3 
successive pairs were observed (5 ≥ n ≥ 3).
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zigzag FO patterns (5 pairs of FO measurements), 
according to the alternating dark-light period of 
1 min each. dfFO was calculated only if at least 3 
successive pairs were observed (Fig. 1).  Isolated 
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All values were expressed as mean ± SD.  Sta-
tistical analysis was performed with Wilcoxon’s 
rank sum test of correspondence or non-corre-
spondence.  Values of P < 0.05 were considered 
signiﬁcant.
Fig. 2.  Some samples of FO patterns of 5 male test subjects.  The dotted line in each sample shows FO pattern in the 
right eye and the solid line shows that in the left eye.  Control solution: physiological saline.  A, phase A: initial 10 min 
before intravenous injection; B, phase B: following 10 min after the injection; C, phase C: additional 10 min after the 
injection.  A dark arrow in each sample indicates the injection point.  , dark period; , light period (horizontal axis). 




Figures 2 and 3 demonstrate some samples of 
FO patterns obtained in the MTCL (10 mg)- and 
control solution-administered researches in the 
Fig. 3.  Some samples of FO patterns of 5 female test subjects.  The dotted line in each sample shows FO pattern in the 
right eye and the solid line shows that in the left eye.  Control solution: physiological saline.  A, phase A: initial 10 min 
before intravenous injection; B, phase B: following 10 min after the injection; C, phase C: additional 10 min after the 
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male and female test subjects, respectively.  After 
administration of MTCL, markedly ﬂuctuated FO 
patterns were observed in both eyes of each sub-
ject in both groups, especially in the female group 
in phases B and C after administration, compared 
with their FO patterns in phase A before adminis-
tration. 
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Table 1.  The dfFO results obtained in the MTCL (10 mg)- and control solution-administered re-
searches in 10 eyes of 5 male healthy volunteers
     Subject     Measured   MTCL (10 mg)-    Control solution-
Number Age    eye  administered research (μV)   administered research (μV)
  (year)  Phase A Phase B Phase C Phase A  Phase B  Phase C 
     1 22 Right 126.1 170.4 127.0 46.1 49.2 146.3
  Left 116.5 170.4 104.3 46.9 60.9 178.3
     2 21 Right 208.4 224.0 396.0 276.4 197.0 171.2
  Left 238.8 253.5 421.0 320.6 257.4 210.8
     3 23 Right 123.4 183.0 175.0 120.2 150.2 130.0
  Left 147.6 197.4 169.0 144.8 145.8 161.4
     4 22 Right 173.9 172.1 213.7 178.3 158.2 211.3
  Left 165.2 181.0 228.4 218.3 175.7 193.9
     5 21 Right 133.9 193.5 185.5 122.6 157.4 167.8
  Left 159.1 175.7 184.8 160.0 190.4 206.1
         Mean   159.3 192.1 220.5 163.4 154.2 177.7
           SD   39.4 27.0  105.7 89.4 61.6 27.8
       Statistical analysis
(Wilcoxon’s rank sum test)
NS, not signiﬁcant (P > 0.05)
Control solution: physiological saline. 
Phase A: initial 10 min before intravenous injection.  Phase B: following 10 min after the injection.  Phase C: addi-
tional 10 min after the injection. 
Table 2.  The dfFO results obtained in the MTCL (10 mg)- and control solution-administered re-
searches in 10 eyes of 5 female healthy volunteers
     Subject     Measured   MTCL (10 mg)-    Control solution-
Number Age    eye  administered research (μV)   administered research (μV)
  (year)  Phase A Phase B Phase C Phase A  Phase B  Phase C 
      6 20 Right 391.8 1235.5 539.7 308.0 269.2 314.8
  Left 453.0 1203.5 499.0 345.6 363.4 352.8
      7 19 Right 60.4 79.3 100.3 28.4 79.0 86.2
  Left 64.0 61.0 79.0 36.8 58.2 88.4
      8 21 Right 156.4 150.0 250.5 110.4 223.0 69.0
  Left 120.6 152.0 266.0 149.8 178.4 99.0
      9 24 Right 219.2 267.6 186.2 198.0 137.6 160.8
  Left 189.6 186.2 146.2 188.2 127.8 156.4
    10 25 Right 259.0 293.0 274.3 246.6 162.5 193.2
  Left 271.4 522.3 314.0 289.0 261.0 233.8
         Mean   210.3 443.8 265.5 190.1 186.0 175.4
           SD   130.2 415.0 154.5 109.9 94.0 98.8
       Statistical analysis
(Wilcoxon’s rank sum test)
NS, not signiﬁcant (P > 0.05)
Control solution: physiological saline. 
Phase A: initial 10 min before intravenous injection.  Phase B: following 10 min after the injection.  Phase C: addi-
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 It is of note that a 20-year-old female (Subject 
6) showed a highly ﬂuctuated FO pattern associ-
ated with increased FO potential after administra-
tion of MTCL in phase B, though no remarkable 
changes were observed in her FO pattern after 
administration of the physiological saline control 
solution in phase B (Fig. 3).
 
Main examination
dfFO results obtained in the male and female 
groups
 After administration of MTCL, the mean 
level of dfFO significantly increased between 
phase A and phase B in the male and female 
groups (P < 0.01 and P < 0.025) and between 
phase A and phase C in both groups (P < 0.01 
and P < 0.05), though no statistically signiﬁcant 
differences (P > 0.05) were detected in the mean 
level of dfFO between phase B and phase C in ei-
ther the male or female group (Tables 1 and 2).
 
Comparison of dfFO values between the 2 groups
 In comparing the dfFO values between the 
two groups, the mean level of dfFO of the 10 eyes 
of the 5 female test subjects was significantly 
higher than that of the 10 eyes of the 5 male test 
subjects in phase B (P < 0.05), though no sta-
tistically significant differences (P > 0.05) were 
detected in the mean level of dfFO in phase A or 




The control examination using physiological 
saline was performed at least 2 weeks after the 
main examination. No statistically signiﬁcant dif-
ferences (P > 0.05) were detected in the mean lev-
els of dfFO in either the male or female group in 
the comparison of the dfFO values in phase A be-
tween control solution-administration and MTCL 
(10 mg)-administration (Tables 1 and 2), though 
relatively larger ﬂuctuations in FO potential were 
apparently observed in the female sample cases 
than in the male ones (Figs. 2 and 3).
 After administration of the control solution, 
no statistically signiﬁcant differences (P > 0.05) 
were detected in the mean level of dfFO in either 
the male or female group throughout the experi-
ment (Tables 1 and 2), even in the comparison of 
the dfFO values between the two groups (Table 3).
 
Table 3.  Comparison of the dfFO values obtained in the MTCL (10 mg)- and control solution-ad-
ministered researches in the male and female groups (10 eyes of 5 healthy volunteers each)
    Research Statistical   Male group (μV)   Female group (μV)
 analysis† Phase A Phase B Phase C  Phase A Phase B Phase C
MTCL (10 mg)- Mean 159.3 192.1 220.5 210.3 443.8 265.5
administered SD 39.4 27.0 105.7 130.2 415.0 154.5
Control solution- Mean 163.4 154.2 177.7 190.1 186.0 175.4
administered  SD 89.4 61.6 27.8 109.9 94.0 98.8
† Wilcoxon’s rank sum test: NS, not signiﬁcant (P > 0.05). 
 Control solution: physiological saline. 
 Phase A: initial 10 min before intravenous injection.  Phase B: following 10 min after the injection.   Phase C: addi-











In the present study, the measuring time of 30 min 
was tentatively divided into 3 phases (A, B and 
C) of 10 min each, and the results obtained from 
each phase were compared with one another, to 
minimize the inﬂuence of SO on FO (Kolder and 
Brecher, 1965; Kolder, 1974; Nikara et al., 1974; 
De Rouck and Kayembe, 1981; Thaler et al., 1982; 
Welber, 1989) and to reﬂect on reaction time after 
MTCL administration (Schulze-Delrieu, 1979; 
Maruiwa et al., 1992).
 The ratio of the osmotic pressure from 
Primperan injection which was adopted in the 
present survey is approximately 1.0 to physiologi-
cal saline used as a control solution.  Thus it is 
difﬁcult to imagine that the osmotic pressure in 
the blood might inﬂuence the FO potential (Ka-
wasaki et al., 1977; Dawis et al., 1985; Shirao 
et al., 1987). Though the pH of this injection is 
relatively low (2.5 to 4.5), it may be presumed 
that the pH in the blood would scarcely change 
after administration of this agent due to the small 
amount in the injection (2 mL) and buffer reac-
tion in the blood, evoking no inﬂuences on the FO 
potential as well as in the SO potential (Maruiwa 
et al., 1992).
 The agent’s permeation into the intraocular 
portion is unclear, but MTCL passes through 
the blood-brain barrier (Schulze-Delrieu, 1979; 
Maruiwa et al., 1992).  Thus it is thought that its 
permeation into the retinal side may be brought 
about through the blood-retinal barrier.
 In the present study, the mean value of dfFO 
signiﬁcantly increased between phase A (the ini-
tial 10 min before intravenous injection of 10 mg 
of MTCL) and phase B (the 10 min after injec-
tion) in the male and female groups (P < 0.01 and 
P < 0.025) and between phase A and phase C (the 
additional 10 min after injection) in both groups 
(P < 0.01 and P < 0.05) (Tables 1 and 2).  This 
indicates that the effects of the dopamine recep-
tor blocker on the FO potential were longer than 
expected.
 It is widely accepted that the retinal neu-
rotransmitter dopamine interacts with two major 
types of dopamine receptors: the D1 and D2 dopa-
mine receptors (Kebabian and Calne, 1979). Each 
receptor has its own agonists and antagonists (Ke-
babian and Calne, 1979; Dubocovich and Weiner, 
1985; Tran and Dickman, 1992).
 In the mammalian retina, the D1 dopamine 
receptors are mostly concentrated in the inner 
plexiform, the inner nuclear and ganglion cell lay-
ers; they are scarcely present in the outer nuclear 
layer or the photoreceptor inner and outer seg-
ments, while the D2 dopamine receptors are pres-
ent in the outer retinal layers—the rods, cones 
and the retinal pigment epithelium (Dearry and 
Brunside, 1988; Gallmore and Steinberg, 1990; 
Tran and Dickman, 1992).
 The D1 dopamine receptors are linked to 
the stimulation of adenylate cyclase and increase 
cAMP, whereas the D2 dopamine receptors are 
coupled negatively to adenylate cyclase and de-
crease cAMP.  That is, the D1 and D2 dopamine 
receptors are localized differentially in the retina 
to mediate different physiologic effects of dopa-
mine (Tran and Dickman, 1992).
 Thus it is supposed that a blockade of dopa-
minergic D2 autoreceptor by MTCL may acceler-
ate the release of endogenous dopamine from the 
inner retinal layers through negative feedback 
(Dubocovich and Weiner, 1985; Maruiwa et al., 
1992; Tran and Dickman, 1992).  Some endog-
enous dopamine would reach to the outer retinal 
layers by diffusion or through inter-plexiform 
cells in the retina (Nguyen-Legros et al., 1989; 
Tran and Dickman, 1992), and bring about a hy-
perpolarized change in the basal membrane of 
the retinal pigment epithelium associated with 
increased electric resistance of the basal mem-
brane.  At the same time, hyperpolaric response 
of visual cells to light stimuli suppressed by 
MTCL (Maruiwa et al., 1992) would bring about 
the decrease of sensitivity of visual cells to light 
stimulation, resulting in irregularly ﬂuctuated FO 
patterns associated with increased FO potential 
and increase of the dfFO values in MTCL (10 
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mg)-administration in the present survey. How-
ever, it is thought that direct erethism by released 
endogeneous dopamine is a rare possibility in the 
retinal pigment epithelium.
 Accordingly, it may be presumed that such 
a dopaminergic reaction in the outer retinal lay-
ers, especially in the retinal pigment epithelium 
which was observed in the present FO study, may 
be brought about by a direct effect of MTCL on 
the D2 dopamine receptors in the retinal pigment 
epithelium even in man.
 In the main examination, the mean level of 
dfFO of the female group was signiﬁcantly higher 
than that of the male group in phase B (P < 0.05) 
(Table 3).  As a control, the experimental pro-
cedure was performed with physiological saline 
administration, and no changes were observed. 
The data suggest that there exists some difference 
between young males and females concerning 
sensitivity to dopamine, as previously postulated 
by Nakao and others (1994) and that young fe-
males may show a higher-than-male sensitivity to 
dopamine in the occurrence of the FO potential, 
as partly demonstrated in the present study (Figs. 
2 and 3).
 The reason why a stronger reaction to do-
pamine is revealed in young females could be 
because:  i) the physiologic effects of dopamine 
which are mediated by speciﬁc receptors on target 
neurons are stronger in females; ii) the sensitivity 
to dopamine itself is higher in females; and iii) 
speciﬁc dopamine receptors in the retina are more 
numerous in females than in males.
 Further investigation on more test subjects 
is needed to clarify the exact reason and mecha-
nisms causing this difference based on sex in the 
young generation concerning sensitivity to dopa-
mine, with special emphasis on the difference in 
sex in much younger or older people, in addition 
to in vivo and in vitro animal experiments.
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